UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000061125 |
|---|---|
| Receipt number | R000069938 |
| Scientific Title | Treatment of Advanced Ovarian and Fallopian Tube Cancer Using Integrated Genomic Diagnostics via Ultrasound-Guided Fine-Needle Biopsy |
| Date of disclosure of the study information | 2026/04/06 |
| Last modified on | 2026/03/31 18:31:19 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Treatment of Advanced Ovarian and Fallopian Tube Cancer Using Integrated Genomic Diagnostics via Ultrasound-Guided Fine-Needle Biopsy
Acronym
Treatment of Advanced Ovarian and Fallopian Tube Cancer Using Integrated Genomic Diagnostics via Ultrasound-Guided Fine-Needle Biopsy
Scientific Title
Treatment of Advanced Ovarian and Fallopian Tube Cancer Using Integrated Genomic Diagnostics via Ultrasound-Guided Fine-Needle Biopsy
Scientific Title:Acronym
Treatment of Advanced Ovarian and Fallopian Tube Cancer Using Integrated Genomic Diagnostics via Ultrasound-Guided Fine-Needle Biopsy
Region
| Japan |
Condition
Condition
Advanced ovarian and fallopian tube cancer
Classification by specialty
| Obstetrics and Gynecology |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
The objective is to establish a system for selecting first-line therapy based on integrated analysis using genomic panel testing in ovarian cancer, using ultrasound-guided needle biopsy.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Evaluation of the feasibility of conducting an integrated analysis using histological diagnosis via ultrasound-guided biopsy and genomic panel testing in the initial treatment of advanced ovarian and fallopian tube cancer
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 90 | years-old | >= |
Gender
Female
Key inclusion criteria
Patients currently receiving outpatient care at Kagoshima University Hospital who are 20 years of age or older and capable of providing informed consent, and who are suspected of having ovarian or fallopian tube cancer
Key exclusion criteria
Other than the above
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | Shintaro |
| Middle name | |
| Last name | Yanazume |
Organization
Kagoshima University Hospital
Division name
Department of Obstetrics and Gynecology
Zip code
890-8520
Address
8-35-1 Sakuragaoka, Kagoshima City
TEL
0992755423
s-yana@m3.kufm.kagoshima-u.ac.jp
Public contact
Name of contact person
| 1st name | Shintaro |
| Middle name | |
| Last name | Yanazume |
Organization
Kagoshima University Hospital
Division name
Department of Obstetrics and Gynecology
Zip code
8920804
Address
8-35-1 Sakuragaoka, Kagoshima City
TEL
0992755423
Homepage URL
s-yana@m3.kufm.kagoshima-u.ac.jp
Sponsor or person
Institute
Kagoshima University
Institute
Department
Personal name
Shintaro Yanazume
Funding Source
Organization
Others
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Japanese
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Department of Obstetrics & Gynecology, Faculty of Medicine, Kagoshima University
Address
8-35-1 Sakuragaoka, Kagoshima City
Tel
0992755423
s-yana@m3.kufm.kagoshima-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
鹿児島県
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 04 | Month | 06 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2023 | Year | 12 | Month | 19 | Day |
Date of IRB
| 2023 | Year | 12 | Month | 19 | Day |
Anticipated trial start date
| 2023 | Year | 12 | Month | 20 | Day |
Last follow-up date
| 2032 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
For patients visiting our department, we will establish and evaluate the safety of ultrasound-guided biopsy techniques for tissue collection during the initial treatment of advanced ovarian and fallopian tube cancer, and verify the feasibility of integrated analysis using histopathological diagnosis and genomic panel testing.
Management information
Registered date
| 2026 | Year | 04 | Month | 01 | Day |
Last modified on
| 2026 | Year | 03 | Month | 31 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069938
